Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs) developed as a targeted treatment approach to deliver toxins directly to cancer cells are one of the fastest growing classes of oncology therapeutics, with eight ADCs and two immunotoxins approved for clinical use. However, selection of an optimum target and payload c...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Ricarda M., Mele, Silvia, Cheung, Anthony, Larcombe-Young, Daniel, Bucaite, Gintare, Sachouli, Eirini, Zlatareva, Iva, Morad, Hassan O. J., Marlow, Rebecca, McDonnell, James M., Figini, Mariangela, Lacy, Katie E., Tutt, Andrew J. N., Spicer, James F., Thurston, David E., Karagiannis, Sophia N., Crescioli, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264231/
https://www.ncbi.nlm.nih.gov/pubmed/32483228
http://dx.doi.org/10.1038/s41598-020-65860-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264231/
https://www.ncbi.nlm.nih.gov/pubmed/32483228
http://dx.doi.org/10.1038/s41598-020-65860-x

Ejemplares similares